drug costs

The governors square off in a first-of-its-kind debate Thursday. Let's compare the political rivals’ health care positions, showing how their policies helped — or hinder— the health of their states’ residents.

A rule taking effect Jan. 1 was intended to stop one set of abuses by pharmacy benefit managers, but some pharmacists say it’s enabling these price brokers to simply do new things unfairly.

The CDC’s RSV vaccination recommendations beg the question: How much should an immunization that will possibly be given to millions of Americans cost to be truly valuable?

Joe Biden's pick for the post next goes to a floor vote, but not before committee Chair Bernie Sanders tried to tie it to reducing the cost of prescription drugs.

The FDA had been expected to decide by next week, but a back-and-forth between state and federal officials about details of the proposal means the wait will continue, a court document says.

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

Before COVID, hepatitis C held the distinction of claiming more American lives each year than any other infectious disease — that’s despite the marketing of several relatively affordable, highly effective treatments.

Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.

The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?

With a decision expected this fall on whether Florida can import cost-saving drugs, the state lashed out after federal officials raised issues such as a requirement for a secured warehouse in Michigan.